GSK-3

GSK-3

Two isoforms, alpha and beta, make up the multifunctional serine/threonine kinase known as glycogen synthase kinase-3 (GSK-3). It controls the receptor tyrosine kinase, cytokine, and Wnt signaling pathways negatively and is highly conserved. Inhibiting GSK-3 through the stimulation of these pathways affects a variety of downstream effectors, such as transcription factors, nutrient sensors, glycogen synthesis, mitochondrial function, circadian rhythm, and cell fate. In response to T-cell receptor activation, GSK-3 also controls alternative splicing, and current phosphoproteomic studies have shown that numerous splicing regulators and splicing factors are phosphorylated in a GSK-3-dependent manner.
Alzheimer's disease (AD) and other neurodegenerative pathologies, as well as other types of diseases like diabetes, cardiovascular problems, and cancer, are caused by the dysfunction or abnormal activity of GSK-3. GSK-3 is a prime candidate for therapeutic intervention because it is also connected to innate immune defense against pathogens.

GSK-3 related products

Structure Cat No. Product Name CAS No. Product Description
V69839 (E/Z)-GSK-3β inhibitor 1 3367-88-2 (E/Z)-GSK-3β inhibitor 1 is the racemate of (E)-GSK-3β inhibitor 1 and (Z)-GSK-3β inhibitor 1.
V69853 (R)-BRD3731 2056262-08-7 (R)-BRD3731 is a GSK3 inhibitor (antagonist) with IC50s of 1.05 and 6.7 μM for GSK3β and GSK3α, respectively.
V0224 1-Azakenpaullone (1-Akp) 676596-65-9 1-Azakenpaullone(1-Akp), an analog of kenpaullone, is a novel, ATP-competitive and selective inhibitor of GSK-3β (glycogen synthase kinase 3β) with potentialantidiabetic and neuroprotective activities.
V69852 2B-(SP) 186901-17-7 2B-(SP) is an eIF2B-based glycogen synthase kinase-3 (GSK-3) substrate.
V77571 2B-(SP) (TFA) 2B-(SP) TFA is an eIF2B-based glycogen synthase kinase-3 (GSK-3) substrate.
V69845 6-Me-ATP (N6-Methyl-ATP) 3130-39-0 6-Me-ATP (N6-Methyl-ATP) is an N6-modified ATP analogue.
V77676 6-Me-ATP trisodium (N6-Methyl-ATP trisodium) 6-Me-ATP (N6-Methyl-ATP) trisodium is an N6-modified ATP analogue.
V9740 9-ING-41 1034895-42-5 9-ING-41 is a glycogen synthase kinase-3 (GSK-3) inhibitor that induces apoptosis and cell cycle arrest at prophase by targeting centrosomes and microtubule-bound GSK-3β.
V69859 AChE/BACE1/GSK3β-IN-1 2866066-81-9 AChE/BACE1/GSK3β-IN-1 is an orally bioactive triple inhibitor of AChE/BACE1/GSK3β.
V0221 AR-A014418 (SN-4521; GSK 3β inhibitor VIII) 487021-52-3 AR-A014418 (AR 0133418; SN4521; GSK-3β inhibitor VIII; AR 014418) is a novel, potent, ATP-competitive, and selective inhibitor of GSK3β (Glycogen Synthase Kinase 3β) with the potential for neurodegenerative diseases.
V0220 AZD1080 612487-72-6 AZD1080 is a selective, potent,orally bioactive, and brain permeable GSK3 (glycogen synthase kinase-3) inhibitor with neuroprotective effects.
V0219 AZD2858 486424-20-8 AZD2858 is a novel, potent, orally bioactive, and selective GSK-3 (glycogen synthase kinase-3) inhibitor with the potential to be used in fracture healing.
V0227 Bikinin (Abrasin) 188011-69-0 Bikinin (also known as Abrasin), apyridinylamido compound, is a novel, potent, non-steroidal and ATP-competitive inhibitor of Arabidopsis GSK-3 (Glycogen synthase kinase 3).
V0228 BIO-acetoxime (GSK-3 Inhibitor X; BIA) 667463-85-6 BIO-acetoxime (also known asGSK-3 Inhibitor X;BIA),a synthetic derivative of a compound from the Mediterranean mollusk Hexaplex trunculus, is a novel, potent and selective dual inhibitor of GSK3α/β (glycogen synthase kinase-3) with potentialanti-infection andanticonvulsant as well as anticancereffects.
V37593 BRD0705 2056261-41-5 BRD0705 is a novel, potent,paralog selectiveand orally bioactive glycogen synthase kinase 3α (GSK3α) inhibitor with an IC50 of 66 nM and a Kd of 4.8 μM.
V69851 BRD3731 2056262-07-6 BRD3731 is a selective GSK3β inhibitor (antagonist) with IC50s of 15 nM and 215 nM for GSK3β and GSK3α respectively.
V4053 BRD5648 2056261-42-6 BRD-5648 (also known as (R)-BRD-0705) is an inactive (R)-enantiomer of BRD-0705.
V78317 CDK7-IN-20 CDK7-IN-20 is a specific, irreversible inhibitor of CDK7 (CDK) with IC50 of 4 nM.
V0213 CHIR-98014 252935-94-7 CHIR-98014 (also known as CT-98024) is a novel, potent, reversible, cell-permeable inhibitor of GSK-3 (glycogen synthase kinase-3) with potential anti-diabetic activity.
V3199 CP21R7 125314-13-8 CP21R7 (also known CP21) is a potent and highly selectiveGSK-3βinhibitor that can potently activate canonical Wnt signalling with IC(50) of 0.6nM for GSK-3β.
Contact Us Back to top